AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge

AbbVie Inc.

2025-Q3 EPS reported $1.34 vs consensus $1.81 ▼ miss (-26.0%)

Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.
Q3 2025 adjusted EPS guidance revised to $1.74-$1.78 from prior $3.24-$3.28.
Full-year 2025 adjusted EPS guidance lowered to $10.38-$10.58 from $11.88-$12.08.
Previously announced FY guidance excluded Q3 IPR&D; further IPR&D beyond Q3 not forecasted.
Q3 results not finalized; preliminary estimates subject to closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.